Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy

This article was originally published in Start Up

Executive Summary

A year ago, Clovis Oncology secured $145 million in start-up financing, the largest A round ever for a biotech. Now, the firm has mapped out a potential clinical trials and approval track for its first therapeutics program. And under a deal announced in April, development of that first drug, a lipid-conjugated formulation of the chemotherapy drug gemcitabine, will include a companion diagnostic developed and sold by Ventana Medical Systems.

You may also be interested in...



Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Clovis Oncology Seeks $149.5 Million IPO

The Colorado cancer drug maker is seeking financing through the public capital markets.

Start-Up Quarterly Statistics, Q2 2010

Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC091982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel